Form 4: Corcept Therapeutics Director Granted 15,000 Stock Options
Insider Transaction Report
Corcept Therapeutics Inc. Director Gillian Cannon was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.
Summary
- Gillian Cannon, a Director of Corcept Therapeutics Inc. (CORT), was granted 15,000 stock options.
- The options have an exercise price of $72.27 per share.
- The transaction date for this grant was June 10, 2025.
- These options become exercisable ratably in equal installments on each monthly anniversary of June 10, 2025, over a one-year period.
- Vesting is contingent upon Ms. Cannon's continued service on each monthly vesting date.
- The options have an expiration date of June 10, 2035.
- Following this transaction, Ms. Cannon beneficially owns 15,000 derivative securities (stock options) directly.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While a routine compensation event, it signifies continued alignment of a director's interests with the company's long-term performance, which is generally viewed favorably.
Positives
- The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
- This is a standard form of compensation for directors, indicating ongoing commitment and retention.
Future Outlook
The vesting schedule of the stock options, which occurs ratably over a one-year period subject to continued service, indicates an expectation of Gillian Cannon's ongoing tenure as a director.
Management Comments
- The form was signed by Joseph Douglas Lyon, as attorney-in-fact for Gillian M. Cannon, indicating the use of a power of attorney on file with the Commission.
Industry Context
The grant of stock options to a director is a common practice in the pharmaceutical and biotechnology industries, serving as a key component of executive and board compensation packages designed to align leadership incentives with company performance and shareholder value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Structure | The grant of stock options to a director is part of the company's ongoing compensation strategy for its board members, aligning their incentives with long-term shareholder value. | 06/10/2025 | Reinforces alignment between director and shareholder interests, promoting long-term commitment and performance. |
Stakeholder Impact
- Shareholders: The grant of options to a director aims to align the director's financial incentives with shareholder interests, potentially leading to better long-term performance and value creation.
- Employees: While not directly impacting general employees, such compensation practices for leadership can influence overall company culture and compensation philosophy.
Next Steps
- Gillian Cannon's continued service on each monthly vesting date is required for the options to become exercisable.
Key Dates
| Date | Description |
|---|---|
| 06/10/2025 | Date of earliest transaction (stock option grant date) and initial exercisable date. |
| 06/12/2025 | Date the Form 4 was signed by the attorney-in-fact. |
| 06/10/2035 | Expiration date of the granted stock options. |
Keywords
Corcept Therapeutics, CORT, SEC Form 4, Stock Options, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.